Vaidya Sane Ayurved Reports ₹53.66 Crore Half-Year Income
Key highlights
- Vaidya Sane Ayurved reported total income of ₹53.66 crore for the half year ended March 2026.
- Reported PAT was ₹1.71 crore in March 2026, versus ₹2.54 crore in March 2025.
- EBIT declined to ₹2.54 crore from ₹4.77 crore in the comparable prior-year half year.
- Interest expense increased to ₹0.74 crore in March 2026 from ₹0.03 crore a year earlier.
powered by IRIS
Vaidya Sane Ayurved Laboratories Limited reported total income of ₹53.66 crore for the half year ended March 2026, while reported profit after tax stood at ₹1.71 crore, compared with ₹2.54 crore in the half year ended March 2025. The figures show higher income alongside lower operating and net profit in the latest reported half-year period.
Know Vaidya Sane Ayurved Laboratories inside out
Results, valuation, peers and who's buying, in one view.
What did Vaidya Sane Ayurved report for the half year ended March 2026?
Vaidya Sane Ayurved reported net sales turnover of ₹52.44 crore and total income of ₹53.66 crore for the half year ended March 2026. Other income was ₹1.22 crore. Total income was higher than ₹48.15 crore in the preceding half year ended September 2025 and ₹47.05 crore in the corresponding half year ended March 2025.
However, the increase in income did not translate into a higher bottom line. Total expenses were ₹48.24 crore, against ₹41.06 crore in September 2025 and ₹40.32 crore in March 2025. Operating profit was ₹4.19 crore, while EBITDA was ₹5.41 crore. Both measures were below the preceding half-year figures of ₹6.13 crore and ₹7.09 crore, respectively.
Depreciation rose to ₹2.88 crore from ₹1.96 crore a year earlier. Interest expense was ₹0.74 crore, compared with ₹0.03 crore in March 2025 and ₹0.07 crore in September 2025. EBIT consequently stood at ₹2.54 crore, down from ₹4.77 crore in the comparable prior-year period.
How did Vaidya Sane Ayurved's profit change from the previous periods?
Vaidya Sane Ayurved recorded profit before tax of ₹1.80 crore for the March 2026 half year and profit after tax of ₹1.71 crore. Reported PAT was also ₹1.71 crore, with no extraordinary items recorded in the period.
The reported PAT was lower than ₹3.22 crore in the half year ended September 2025 and ₹2.54 crore in the half year ended March 2025. Taxes were ₹0.09 crore in the latest period, compared with ₹1.06 crore and ₹1.01 crore in the two comparison periods. The lower tax charge did not offset the decline in EBIT and the increase in interest expense.
The March 2025 reported PAT included an extraordinary item of negative ₹1.20 crore. Profit and loss for that period before the extraordinary item was ₹3.74 crore. This distinction is relevant when comparing reported profit across periods, since the latest March 2026 half-year result did not contain an extraordinary item.
Got a follow-up? Ask IRIS
What disclosures has Vaidya Sane Ayurved made to the exchange?
Vaidya Sane Ayurved has informed the exchange that it submitted financial results for the period ended March 31, 2026. The available half-year financial data provides the income, expense and profit measures for the March 2026 period, but the supplied disclosure does not provide quarterly financial figures for the subsequent cycle.
The company had earlier informed the exchange that financial results for the period ended September 30, 2025 had been approved. In the disclosed half-year comparison for that period, total revenue was stated at ₹50.90 crore, profit before tax at ₹6.47 crore and PAT at ₹4.84 crore. Those figures are presented in a separate disclosure and should not be treated as directly interchangeable with the half-year table, which labels total income at ₹48.15 crore for September 2025.
Vaidya Sane Ayurved also informed the exchange about a notice for its annual general meeting scheduled for September 30, 2026. The supplied material does not state the resolutions, shareholder decisions or outcomes of that meeting.
Why do the March 2026 figures matter to investors?
The March 2026 figures show that Vaidya Sane Ayurved's total income rose by ₹6.61 crore from the corresponding March 2025 half year, while reported PAT fell by ₹0.83 crore. Expenses increased by ₹7.92 crore over the same comparison. This places the relationship between revenue growth, costs and profitability at the centre of the reported financial update.
The change in interest expense is also material in the period comparison. Interest increased from ₹0.03 crore in March 2025 to ₹0.74 crore in March 2026, while EBIT declined from ₹4.77 crore to ₹2.54 crore. The figures show that the company generated a larger top line but a lower level of earnings before and after tax.
For investors, the available data offers a half-year view rather than a complete quarterly update for the next reporting cycle. The supplied information says quarterly financials were not yet fully available through certain data partners and directs investors to NSE and BSE filings and Screener.in for cross-checking. It identifies July-August 2026 only as an indicative window for Q1 FY27 results.
Conclusion
Vaidya Sane Ayurved's March 2026 half-year results show higher total income of ₹53.66 crore but lower profitability, with reported PAT of ₹1.71 crore. The key reported movements were an increase in total expenses, lower EBITDA and EBIT, and higher interest expense compared with the March 2025 half year.
Investors can watch for the company's next financial disclosure and the availability of quarterly figures for Q1 FY27, which the supplied information places in an indicative July-August 2026 reporting window. The source also discloses an annual general meeting notice dated September 30, 2026, without providing details of resolutions or outcomes.